MAP3K5 and metabolic dysfunction-associated steatohepatitis: ASK1 is associated with development of fibrosis in various tissues and is a therapeutic target for fibrotic diseases, including pulmonary arterial hypertension, chronic kidney disease, and nonalcoholic steatohepatitis.